Orchid Pharma balance sheet

As of Mar 2026

Total assets: ₹2,258cr+33.8% on Mar 2025
Shareholders' equity: ₹1,564cr+23.4% on Mar 2025
Total debt: ₹301cr+73.0% on Mar 2025
Cash and investments: ₹7.1cr−66.5% on Mar 2025

₹ crore except per share

Tap a line for its trend	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Current assets
Non-current assets					FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	687	632	619	573
	341	64.5	16.4	46.5
	0.0	1.1	0.0	0.0
	0.6	0.0	0.6	0.4
	73.1	16.2	14.3	—
	67.0	49.7	45.8	44.4
	11.5	4.3	6.0	6.9
	78.5	53.9	51.8	51.3
	59.9	51.3	51.3	51.3
	89.9	61.8	9.8	2.0
	1,329	880	763	724
	372	326	264	229
	381	242	196	215
	7.1	21.1	3.6	22.6
	76.4	159	263	8.0
	1.3	3.0	4.5	0.2
	466	425	467	246
	90.5	53.8	58.3	25.3
	929	807	791	501
	2,258	1,688	1,554	1,225
Equity
	59.9	50.7	50.7	40.8
	1,504	1,217	1,119	648
	1,564	1,267	1,169	689
	1,564	1,267	1,169	689
Liabilities
	185	132	120	149
	4.7	0.0	—	—
	189	132	120	149
	13.4	3.4	3.6	12.6
	0.0	0.0	—	3.2
	—	0.0	0.4	—
	203	135	124	165
	117	42.6	14.0	183
	347	222	230	182
	1.7	0.0	—	—
	465	265	244	364
	0.8	2.4	2.1	3.5
	25.3	18.5	14.3	4.1
	491	286	260	372
	694	421	384	537
	2,258	1,688	1,554	1,225
Assets — additional as-filed lines
	0.3	2.8	1.6	1.0
Trade payables — MSME split
	10.3	11.0	—	—
	336	211	—	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ORCHPHARMA₹865.00

Orchid Pharma Limited

· Pharma & Health

₹ CrorePeersFDC GUJTHEM IOLCP MOREPENLAB RPGLIFE GUFICBIO INNOVACAP UNICHEMLABMcap ₹5,180 Cr

View

In ₹ Crore except Per Share As of	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Non-current Assets
+ Property, Plant & Equipment	572.7	618.9	631.6	686.6	686.6
+ Capital Work-in-Progress	46.5	16.4	64.5	340.5	340.5
+ Goodwill	0.0	0.0	1.1	0.0	0.0
+ Other Intangibles	0.4	0.6	0.0	0.6	0.6
+ Intangibles under Development	—	14.3	16.2	73.1	73.1
+ Non-current Investments	44.4	45.8	49.7	67.0	67.0
+ Other Non-current Financial Assets	6.9	6.0	4.3	11.5	11.5
Non-current Financial Assets	51.3	51.8	53.9	78.5	78.5
+ Deferred Tax Assets	51.3	51.3	51.3	59.9	59.9
+ Other Non-current Assets	2.0	9.8	61.8	89.9	89.9
Total Non-current Assets	724.2	763.1	880.5	1,329.2	1,329.2
Current Assets
+ Inventories	228.7	264.2	326.4	372.3	372.3
+ Trade Receivables	215.2	195.5	241.8	381.4	381.4
+ Cash & Cash Equivalents	22.6	3.6	21.1	7.1	7.1
+ Other Bank Balances	8.0	263.0	158.5	76.4	76.4
+ Other Current Financial Assets	0.2	4.5	3.0	1.3	1.3
Current Financial Assets	246.0	466.6	424.5	466.2	466.2
+ Other Current Assets	25.3	58.3	53.8	90.5	90.5
Total Current Assets	501.0	790.8	807.4	929.3	929.3
Total Assets	1,225.2	1,553.9	1,687.9	2,258.4	2,258.4
Equity
+ Equity Share Capital	40.8	50.7	50.7	59.9	59.9
+ Other Equity / Reserves	647.8	1,118.7	1,216.6	1,504.4	1,504.4
Equity — Owners of Parent	688.6	1,169.5	1,267.3	1,564.3	1,564.3
Total Equity	688.6	1,169.5	1,267.3	1,564.3	1,564.3
Liabilities
+ Borrowings — Non-current	148.8	120.4	131.6	184.7	184.7
+ Other Non-current Financial Liab	—	—	0.0	4.7	4.7
Non-current Financial Liabilities	148.8	120.4	131.6	189.5	189.5
+ Provisions — Non-current	12.6	3.6	3.4	13.4	13.4
+ Deferred Tax Liabilities	3.2	—	0.0	0.0	0.0
+ Other Non-current Liabilities	—	0.4	0.0	—	—
Non-current Liabilities	164.7	124.4	135.1	202.9	202.9
+ Borrowings — Current	182.5	14.0	42.6	116.7	116.7
+ Trade Payables	181.8	229.6	222.1	346.7	346.7
+ Other Current Financial Liab	—	—	0.0	1.7	1.7
Current Financial Liabilities	364.3	243.6	264.7	465.1	465.1
+ Provisions — Current	3.5	2.1	2.4	0.8	0.8
+ Other Current Liabilities	4.1	14.3	18.5	25.3	25.3
Current Liabilities	371.9	260.0	285.6	491.2	491.2
Total Liabilities	536.6	384.4	420.6	694.1	694.1
Total Equity & Liabilities	1,225.2	1,553.9	1,687.9	2,258.4	2,258.4
Assets — additional as-filed lines
+ Current Tax Assets	1.0	1.6	2.8	0.3	0.3
Trade Payables — MSME split
+ Dues to Micro & Small — Current	—	—	11.0	10.3	10.3
+ Dues to Other Creditors — Current	—	—	211.1	336.4	336.4

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.